GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Indaptus Therapeutics Inc (NAS:INDP) » Definitions » Dividend Payout Ratio

Indaptus Therapeutics (Indaptus Therapeutics) Dividend Payout Ratio : 0.00 (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Indaptus Therapeutics Dividend Payout Ratio?

Indaptus Therapeutics's dividend payout ratio for the months ended in Dec. 2023 was 0.00.

The historical rank and industry rank for Indaptus Therapeutics's Dividend Payout Ratio or its related term are showing as below:


INDP's Dividend Payout Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 0.43
* Ranked among companies with meaningful Dividend Payout Ratio only.

As of today (2024-04-28), the Dividend Yield % of Indaptus Therapeutics is 0.00%.

Indaptus Therapeutics's Dividends per Share for the months ended in Dec. 2023 was $0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.


Indaptus Therapeutics Dividend Payout Ratio Historical Data

The historical data trend for Indaptus Therapeutics's Dividend Payout Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Indaptus Therapeutics Dividend Payout Ratio Chart

Indaptus Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Dividend Payout Ratio
- - - -

Indaptus Therapeutics Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Dividend Payout Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Indaptus Therapeutics's Dividend Payout Ratio

For the Biotechnology subindustry, Indaptus Therapeutics's Dividend Payout Ratio, along with its competitors' market caps and Dividend Payout Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Indaptus Therapeutics's Dividend Payout Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Indaptus Therapeutics's Dividend Payout Ratio distribution charts can be found below:

* The bar in red indicates where Indaptus Therapeutics's Dividend Payout Ratio falls into.



Indaptus Therapeutics Dividend Payout Ratio Calculation

Dividend payout ratio measures the percentage of the company's earnings paid out as dividends.

Indaptus Therapeutics's Dividend Payout Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Dividend Payout Ratio=Dividends per Share (A: Dec. 2023 )/ EPS without NRI (A: Dec. 2023 )
=0/ -1.83
=N/A

Indaptus Therapeutics's Dividend Payout Ratio for the quarter that ended in Dec. 2023 is calculated as

Dividend Payout Ratio=Dividends per Share (Q: Dec. 2023 )/ EPS without NRI (Q: Dec. 2023 )
=0/ -0.47
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Indaptus Therapeutics (NAS:INDP) Dividend Payout Ratio Explanation

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.


Indaptus Therapeutics Dividend Payout Ratio Related Terms

Thank you for viewing the detailed overview of Indaptus Therapeutics's Dividend Payout Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Indaptus Therapeutics (Indaptus Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
3 Columbus Circle, 15th Floor, New York, NY, USA, 10019
Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company's pre-clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma in standard pre-clinical models.
Executives
Glen R. Anderson 10 percent owner 3274 ROSS ROAD, PALO ALTO CA 94303
Roger J. Waltzman officer: Chief Medical Officer C/O JAGUAR ANIMAL HEALTH, INC., 201 MISSION STREET, SUITE 2375, SAN FRANCISCO CA 94105
Robert Martell director 4 MAGUIRE ROAD, LEXINGTON MA 02421
Boyan Vesselinov Litchev officer: Chief Medical Officer 13357 RUSSET LEAF LN., SAN DIEGO CA 92129
Jeffrey A Meckler director, officer: Chief Executive Officer 740 BROADWAY, 9TH FLOOR, NEW YORK NY 10003
Walt Addison Linscott officer: Chief Business Officer 1860 MONTREAL ROAD, TUCKER GA 30084
Michael James Newman director, 10 percent owner, officer: Chief Scientific Officer C/O INTEC PARENT, INC., 12 HARTOM ST., HAR HOTZVIM, JERUSALEM L3 9777512
Mark John Gilbert director 13731 NORTHWOOD RD., NW, SEATTLE WA 98177
Brian O'callaghan director 550 HILLS DRIVE, 3RD FLOOR, BEDMINSTER NJ 07921
Hoonmo Lee director, 10 percent owner C/O INTEC PARENT, INC., 12 HARTOM ST., HAR HOTZVIM, JERUSALEM L3 9777512
Anthony J Maddaluna director PFIZER INC. ATTN CORPORATE SECRETARY, 235 RAST 42ND STREET, NEW YORK NY 10017
William B Hayes director 231 MAPLE AVENUE, BURLINGTON NC 27215
Roger Pomerantz director 711 HARVEST HILL ROAD, CHALFONT PA 18914
Hila Karah director 9 HALAMISH STREET, CAESAREA INDUSTRIAL PARK, CAESAREA L3 38900
Nir Sassi officer: Chief Financial Officer 3 ELUL STREET, APT. 6, MODIIN L3 7176397

Indaptus Therapeutics (Indaptus Therapeutics) Headlines

From GuruFocus